aTyr Pharma Inc
NASDAQ:ATYR

Watchlist Manager
aTyr Pharma Inc Logo
aTyr Pharma Inc
NASDAQ:ATYR
Watchlist
Price: 3.91 USD -1.51%
Market Cap: 328.2m USD
Have any thoughts about
aTyr Pharma Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-3.9
Current
-2.3
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-3.9
=
Enterprise Value
263.2m USD
/
EBITDA
-67.3m USD
All Countries
Close
Market Cap EV/EBITDA
US
aTyr Pharma Inc
NASDAQ:ATYR
328.2m USD -3.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 529.4
US
Abbvie Inc
NYSE:ABBV
315.6B USD 15.4
US
Amgen Inc
NASDAQ:AMGN
140.4B USD 15.9
US
Gilead Sciences Inc
NASDAQ:GILD
113.3B USD 10
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD 21.6
US
Epizyme Inc
F:EPE
94.1B EUR -512.3
AU
CSL Ltd
ASX:CSL
138.1B AUD 20.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.2B USD 15.7
US
Seagen Inc
F:SGT
39.3B EUR -58.5
NL
argenx SE
XBRU:ARGX
37.3B EUR -163.2
EBITDA Growth EV/EBITDA to Growth
US
aTyr Pharma Inc
NASDAQ:ATYR
Average EV/EBITDA: 16.5
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 529.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
15.9
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.3 N/A N/A
AU
CSL Ltd
ASX:CSL
20.2
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.7
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -163.2 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-3.9
2-Years Forward
EV/EBITDA
-3.3
3-Years Forward
EV/EBITDA
-3.5